The agreement to sell was announced on May 8, 2017
Claris Lifesciences has recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India; the joint venture with Otsuka Pharmaceutical Factory, and Mitsui & Co.; to Otsuka Pharmaceutical Factory, for a consideration of $ 20 million.
In the July, 2017 the company has also completed the sale of its global generic injectables business to Baxter international for an enterprise value of $ 625 million.